Updates on Singapore patent practice

Following a series of public consultation and discussions, the Intellectual Property Office of Singapore (IPOS) has confirmed that they will launch a formal procedure for the submission of “third party observations” under which members of the public will be able notify IPOS of information that might be of relevance to the patentability of an invention […]

A second-round victory for brand drug owners against generics who fail to declare relevant patents under Singapore’s patent linkage regime

Proprietors of brand-name drugs may heave another sigh of relief as the Singapore Court of Appeal in Zyfas Medical Co (Sued as a firm) v. Millennium Pharmaceuticals, Inc [2020] SGCA 84 re-affirmed its holding in Millennium Pharmaceuticals, Inc v. Drug Houses of Australia Pte Ltd [2019] SGCA 31 (the DHA decision) rejecting an overly-restrictive interpretation […]

Salient points concerning the law of anticipation in the case of Element Six Technologies Ltd v. IIa Technologies Pte Ltd.

On February 7, 2020, the Singapore High Court reported its decision in the case of Element Six Technologies Ltd v. IIa Technologies Pte Ltd. [2020] SGHC 26, which treated various issues pertaining to novelty, priority date and anticipation. In particular, there are several interesting points in the decision concerning the law of anticipation which will […]

New Singapore Patent Fast Track Programme to Accelerate Patent Prosecution Timeframe

The Intellectual Property Office of Singapore (IPOS) in its continuing effort to expand support to innovators, launched a new programme named the “SG Patent Fast Track”  on 4 May 2020 to replace the existing patent acceleration programmes, namely FinTech Fast Track and Accelerated Initiative for Artificial Intelligence (“AI2”), which ceased on 25 April 2020 and […]